Core Viewpoint - Longeveron Inc. has received a Type C meeting from the FDA to discuss the clinical efficacy data endpoints and statistical analysis plan for its stem cell therapy laromestrocel, aimed at treating Hypoplastic Left Heart Syndrome (HLHS) in pediatric patients, with top-line trial results expected in Q3 2026 [1][6]. Company Overview - Longeveron Inc. is a clinical stage biotechnology company focused on developing regenerative medicines to address unmet medical needs, with its lead product being laromestrocel (LOMECEL-B®), an allogeneic mesenchymal stem cell therapy derived from young, healthy adult donors [4]. - The company is pursuing three pipeline indications: HLHS, Alzheimer's disease, and Pediatric Dilated Cardiomyopathy (DCM) [4]. - Laromestrocel has received multiple FDA designations, including Orphan Drug, Fast Track, and Rare Pediatric Disease designations for the HLHS program, and Regenerative Medicine Advanced Therapy (RMAT) designation for the Alzheimer's program [4]. Clinical Trial Details - The ELPIS II trial is a Phase 2b clinical study evaluating laromestrocel as an adjunct therapy for HLHS, enrolling 40 pediatric patients across twelve leading treatment institutions [2]. - The trial is conducted in collaboration with the National Heart, Lung, and Blood Institute (NHLBI) through NIH grants [2]. - The anticipated top-line results from the ELPIS II trial are expected in the third quarter of 2026, with a potential Biological License Application (BLA) submission if results are positive [6]. Medical Context - Hypoplastic Left Heart Syndrome (HLHS) is a congenital heart defect characterized by the underdevelopment or absence of the left ventricle, leading to significantly reduced systemic blood flow and requiring complex surgical interventions [3]. - Despite surgical advancements, early mortality remains high in HLHS patients, primarily due to right ventricular failure, indicating a critical unmet medical need for improved treatment options [3][6].